Pacira BioSciences (PCRX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
701.0M
Gross Profit
530.5M
75.69%
Operating Income
97.6M
13.92%
Net Income
-99.6M
-14.20%
EPS (Diluted)
-$2.15
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
775.2M
Shareholders Equity
778.3M
Debt to Equity
1.00
Cash Flow Metrics
Operating Cash Flow
29.3M
Free Cash Flow
178.8M
Revenue & Profitability Trend
Pacira BioSciences Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 701.0M | 675.0M | 666.8M | 541.5M | 429.6M |
| Cost of Goods Sold | 170.4M | 184.7M | 199.3M | 140.3M | 117.3M |
| Gross Profit | 530.5M | 490.3M | 467.5M | 401.3M | 312.3M |
| Operating Expenses | 375.7M | 345.7M | 339.3M | 254.9M | 252.9M |
| Operating Income | 97.6M | 87.3M | 70.9M | 132.8M | 51.5M |
| Pre-tax Income | -63.1M | 61.7M | 13.3M | 56.4M | 20.1M |
| Income Tax | 36.5M | 19.7M | -2.6M | 14.4M | -125.4M |
| Net Income | -99.6M | 42.0M | 15.9M | 42.0M | 145.5M |
| EPS (Diluted) | -$2.15 | $0.89 | $0.34 | $0.92 | $3.33 |
Income Statement Trend
Pacira BioSciences Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 745.1M | 510.0M | 498.3M | 866.0M | 651.6M |
| Non-Current Assets | 808.4M | 1.1B | 1.2B | 1.2B | 622.9M |
| Total Assets | 1.6B | 1.6B | 1.7B | 2.1B | 1.3B |
| Liabilities | |||||
| Current Liabilities | 309.9M | 97.4M | 147.8M | 521.1M | 253.3M |
| Non-Current Liabilities | 465.2M | 606.9M | 758.4M | 823.8M | 401.5M |
| Total Liabilities | 775.2M | 704.3M | 906.2M | 1.3B | 654.8M |
| Equity | |||||
| Total Shareholders Equity | 778.3M | 870.1M | 775.0M | 730.4M | 619.7M |
Balance Sheet Composition
Pacira BioSciences Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -99.6M | 42.0M | 15.9M | 42.0M | 145.5M |
| Operating Cash Flow | 29.3M | 169.4M | 131.7M | 119.2M | 74.8M |
| Investing Activities | |||||
| Capital Expenditures | -10.6M | -15.2M | -30.1M | -45.9M | -37.8M |
| Investing Cash Flow | -83.3M | 77.5M | -225.2M | -20.8M | -277.6M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 15.1M | -187.8M | -428.9M | 717.8M | 174.5M |
| Free Cash Flow | 178.8M | 139.5M | 115.2M | 79.9M | 39.2M |
Cash Flow Trend
Pacira BioSciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
13.14
Forward P/E
8.17
Price to Book
1.43
Price to Sales
1.63
PEG Ratio
8.17
Profitability Ratios
Profit Margin
-14.76%
Operating Margin
4.63%
Return on Equity
-12.27%
Return on Assets
3.56%
Financial Health
Current Ratio
2.42
Debt to Equity
79.70
Beta
0.51
Per Share Data
EPS (TTM)
-$2.24
Book Value per Share
$17.25
Revenue per Share
$15.22
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| pcrx | 1.1B | 13.14 | 1.43 | -12.27% | -14.76% | 79.70 |
| Zoetis | 70.3B | 28.34 | 15.12 | 52.09% | 27.12% | 145.63 |
| Haleon Plc - ADR | 47.2B | 25.01 | 5.88 | 8.95% | 12.84% | 63.41 |
| Supernus | 1.8B | 28.53 | 1.72 | 6.32% | 9.27% | 3.13 |
| Indivior PLC | 1.7B | 530.50 | -6.04 | -0.57% | -5.30% | -1.29 |
| Bausch Health | 2.3B | -47.00 | -9.23 | 14.29% | -0.41% | -89.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.